1. Home
  2. IMMP vs XYF Comparison

IMMP vs XYF Comparison

Compare IMMP & XYF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.90

Market Cap

264.9M

Sector

Health Care

ML Signal

HOLD

XYF

X Financial each representing six

HOLD

Current Price

$5.89

Market Cap

260.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMP
XYF
Founded
1987
2014
Country
Australia
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
264.9M
260.6M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
IMMP
XYF
Price
$2.90
$5.89
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.9M
213.5K
Earning Date
02-22-2026
11-20-2025
Dividend Yield
N/A
9.76%
EPS Growth
N/A
49.84
EPS
N/A
5.72
Revenue
$3,306,742.00
$1,106,908,607.00
Revenue This Year
$292.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$1.00
Revenue Growth
31.28
47.14
52 Week Low
$1.32
$5.44
52 Week High
$3.53
$20.36

Technical Indicators

Market Signals
Indicator
IMMP
XYF
Relative Strength Index (RSI) 65.98 25.96
Support Level $2.52 $5.44
Resistance Level $3.32 $6.74
Average True Range (ATR) 0.22 0.34
MACD 0.04 0.10
Stochastic Oscillator 62.18 23.37

Price Performance

Historical Comparison
IMMP
XYF

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

About XYF X Financial each representing six

X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.

Share on Social Networks: